Group 1 - Health元's stock price increased by 0.99% to 12.21 yuan per share, with a total market capitalization of 22.338 billion yuan and a trading volume of 3.79 billion yuan, marking a cumulative increase of 5.71% over the past seven days [1] - The company, founded on December 18, 1992, and listed on June 8, 2001, operates as a comprehensive pharmaceutical enterprise engaged in the research, development, and production of traditional Chinese medicine, health products, and Western medicine [1] - The main business revenue composition includes: chemical preparations 47.71%, chemical raw materials and intermediates 31.97%, traditional Chinese medicine preparations 10.28%, diagnostic reagents and equipment 4.74%, health food 3.08%, biological products 1.20%, and others 0.86% [1] Group 2 - Longxin Fund has one fund heavily invested in Health元, with Longxin Medical Health Mixed (LOF) A (163001) reducing its holdings by 57,600 shares in the third quarter, now holding 236,000 shares, representing 2.18% of the fund's net value [2] - The fund has generated a floating profit of approximately 28,300 yuan today and a total of 155,800 yuan during the seven-day increase [2] - Longxin Medical Health Mixed (LOF) A (163001) was established on March 26, 2010, with a current scale of 128 million yuan, yielding 8.03% this year and 33.13% over the past year [2]

Group 1 - The company held its 29th meeting of the 11th Board of Directors on December 5, 2025, via telecommunication voting, with all 11 directors present, complying with relevant laws and regulations [1] - The Board approved an adjustment to the expected related party transactions for 2025 with its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., increasing the total expected amount to RMB 166 million, with an additional RMB 37.6 million [2] - The expected amount for energy services was adjusted from RMB 11.8 million to RMB 16 million, and for other labor services from RMB 11.6 million to RMB 45 million, while the amounts for procurement and leasing remained unchanged [2] Group 2 - The proposal involves related party transactions as Health元药业集团股份有限公司 holds a 22.58% stake in Lizhu Monoclonal Antibody, with certain directors abstaining from voting due to conflicts of interest [3] - The proposal was reviewed and approved by the independent directors in a special meeting, with unanimous consent from all independent directors [4] - The voting results showed 7 votes in favor, 0 against, and 0 abstentions [5]

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Health元, indicating a positive trend in stock price and market activity [1][2][3] - As of September 5, Health元's stock price increased by 2.05% to 13.44 CNY per share, with a total market capitalization of 24.588 billion CNY [1] - Year-to-date, Health元's stock has risen by 21.41%, with notable increases of 8.21% over the last five trading days, 9.62% over the last twenty days, and 17.28% over the last sixty days [1] Group 2 - Health元's main business segments include chemical preparations (47.71%), chemical raw materials and intermediates (31.97%), traditional Chinese medicine preparations (10.28%), diagnostic reagents and equipment (4.74%), health food (3.08%), biological products (1.20%), and others (0.86%) [1] - As of June 30, 2025, Health元 reported a revenue of 7.898 billion CNY, a year-on-year decrease of 4.08%, while net profit attributable to shareholders increased by 1.10% to 785 million CNY [2] - The company has distributed a total of 3.979 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]

北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 法律意见 德恒 06F20240039-026 号 致：健康元药业集团股份有限公司 本所律师得到如下保证：公司已提供了本所律师认为出具本法律意见所必需 的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准确、 完整的要求，有关副本、复印件等材料与原始材料一致。 在本法律意见中，本所律师根据《股东会规则》及公司的要求，仅对公司本 次会议的召集、召开程序是否符合有关法律、行政法规、《公司章程》以及《股 东会规则》的有关规定，出席会议人员资格、召集人资格是否合法有效和会议的 表决程序、表决结果是否合法有效发表意见，不对本次会议审议的议案内容以及 这些议案所表述的事实或数据的真实性及准确性发表意见。 健康元药业集团股份有限公司（以下简称"公司"）2024 年年度股东大会 ...

Core Viewpoint - The announcement details a correction regarding the capital increase and related transactions between Lijun Pharmaceutical Group Co., Ltd. and its subsidiary Lijun Biopharmaceutical Co., Ltd., clarifying the financial terms and ensuring compliance with regulatory requirements [1][4][5]. Group 1: Correction of Announcement - The company corrected the amount of capital increase from "RMB 100,000.00 million" for "206,449,050 shares" to "RMB 100,000.00 million" for "RMB 206,449,050" in registered capital [1][5]. - The transaction amount is based on fair negotiations to meet Lijun Biopharmaceutical's funding needs, referencing a previous agreement dated November 17, 2023 [1][5][11]. - The operational scope of Lijun Biopharmaceutical was updated to reflect accurate business activities, including medical research and drug production [1][5]. Group 2: Transaction Overview - The company plans to use its own funds of RMB 100,000.00 million to increase the capital of Lijun Biopharmaceutical to support its R&D projects and daily operations [5][11]. - The transaction constitutes a related party transaction due to the shared ownership with the controlling shareholder, Health元 Pharmaceutical Group Co., Ltd., which holds a 45.96% stake [5][7]. - The board of directors approved the transaction with a unanimous vote, ensuring that related directors abstained from voting [6][18]. Group 3: Financial Impact and Strategic Importance - The transaction amount represents 7.21% of the company's latest audited net assets of RMB 1,386,233.42 million [6]. - The capital increase is intended to enhance the financial structure of Lijun Biopharmaceutical, which is crucial for the development of innovative biopharmaceuticals [15]. - The transaction is not expected to adversely affect the company's financial status or operational results [15].

一、回购股份的基本情况 健康元药业集团 关于股份回购进展公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-011 健康元药业集团股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/26，由董事长朱保国先生提议 | | --- | --- | | 回购方案实施期限 | 2024/9/23~ 2025/9/22 | | 预计回购金额 | 万元 30,000 万元~50,000 | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 4,384.35 万股 | | 累计已回购股数占总股本比例 | 2.34% | | 累计已回购金额 | 48,978.52 万元 | | 实际回购价格区间 | 10.57 元/股~11.90 元/股 | 依据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定， ...